SEARCH 
COMPANIES
Discover the reality of companies and brands!
TRANSNATIONALE.ORG
Free and independant information on large corporations

GlaxoSmithKline

Headquarters : 980 Great West Road TW8 9GS Brentford Middlesex United Kingdom United Kingdom
Job offers, investor relations : web www.gsk.com tel. 44-20 8047 5000 email: anita.e.kidgell@gsk.com stock : GSK analytics

Brands

name
click to compare prices
» Shop local, ethical and at the best price on Ethishop

« Ethical » rating of GlaxoSmithKline , group Glaxo Wellcome PLC and subsidiaries

Jobs -9% /1998 Pollution 1 Fraud 13 Offshore 7 Sales 13 Bn $.€ /year Profit 3 Bn $.€ /1998 Wage 1798 *min. Influence 8 Infocom 7
[click on the rating for the method or on the number for the data]

shareholdercountry%source
Glaxo Wellcome PLCUnited Kingdom59
Smithkline BeechamUnited Kingdom41
» More shareholders of GlaxoSmithKline
year
business
source
2006GlaxoSmithKline sells 23% of the vaccines bought in the world.Les Echos
2006GlaxoSmithKline is Europe's biggest drugmaker.Reuters
2006GlaxoSmithKline is the world's second-largest pharmaceutical group.Les Echos
2004GlaxoSmithKline sells 25% of the tobacco substitutes bought in France.Les Echos
» More business descriptions and market shares for GlaxoSmithKline.
subsidiarycountry%source
Stiefel Laboratories United States of America100Les Echos
» More subsidiaries of GlaxoSmithKline
country
address & contact : production type
incentive source
Brazil Brazil
:
 
China China
Shanghai, Glaxo plans to have 1,000 scientists working at the facility in 10 years. : Production, research facility
 
China China
PharmaValley, Shanghai :
 Les Echos
Egypt Egypt
:
 
El Salvador El Salvador
:
Offshore finance, secret bank account, tax haven, shell companies or free zone(s)
Hong-Kong Hong-Kong
:
Offshore finance, secret bank account, tax haven, shell companies or free zone(s)
Hong-Kong Hong-Kong
:
Offshore finance, secret bank account, tax haven, shell companies or free zone(s)
Ireland Ireland
Dungarvan : R&D
Offshore finance, secret bank account, tax haven, shell companies or free zone(s) Les Echos
Luxembourg Luxembourg
:
Offshore finance, secret bank account, tax haven, shell companies or free zone(s)
Luxembourg Luxembourg
:
Offshore finance, secret bank account, tax haven, shell companies or free zone(s)
Pakistan Pakistan
:
 
Peru Peru
:
 
Philippines Philippines
:
Offshore finance, secret bank account, tax haven, shell companies or free zone(s)
Dominican Republic Dominican Republic
:
Offshore finance, secret bank account, tax haven, shell companies or free zone(s)
Singapore Singapore
:
Offshore finance, secret bank account, tax haven, shell companies or free zone(s)
Singapore Singapore
:
Offshore finance, secret bank account, tax haven, shell companies or free zone(s)
Suriname Suriname
"Bioventure" with Conservation International : bioprospection
 Alternet
Turkey Turkey
:
 
Venezuela Venezuela
:
 

  • Human impact

year name
photo position; compensation
source
2007Garnier, Jean-Pierre
See the photo of: Garnier, Jean-Pierre Chief Executive Officer; salary: 13,81 million Eu€;
Les Echos
2007Witty, Andrew
See the photo of: Witty, Andrew Chief Executive Officer;
2005Gent, Chris
See the photo of: Gent, Chris Chief Executive Officer;
2004Ingram, Bob
See the photo of: Ingram, Bob Vice-president;
2004McHenry, Donald F
See the photo of: McHenry, Donald F Director;
2003Culp, H Lawrence
See the photo of: Culp, H Lawrence Director;
2003Davis, Crispin
See the photo of: Davis, Crispin Director;
2003Dunoyer, Marc
See the photo of: Dunoyer, Marc Chairman;
2003Greig, Russell
See the photo of: Greig, Russell Chairman;
2003Stout, David
See the photo of: Stout, David Chairman;
2003Viehbacher, Christopher
See the photo of: Viehbacher, Christopher Chairman;
2003Wilson, Robert
See the photo of: Wilson, Robert Director;
2003Witty, Andrew
See the photo of: Witty, Andrew Chairman;
2002Hogg, Christopher
See the photo of: Hogg, Christopher Director;
2002McArthur, John
See the photo of: McArthur, John Director;
2002Pulman, David
See the photo of: Pulman, David Chairman;
2002Yamada, Tadataka
See the photo of: Yamada, Tadataka Director;
2001Bondy, Rupert
See the photo of: Bondy, Rupert Vice-president;
2001Calhoun, Ford
See the photo of: Calhoun, Ford Director;
2001Chapiro, Lucy
See the photo of: Chapiro, Lucy Director;
2001Coombe, John
See the photo of: Coombe, John Chief Financial Officer;
2001Job, Peter
See the photo of: Job, Peter Director;
2001Phelan, Daniel
See the photo of: Phelan, Daniel Vice-president;
2001Prosser, Sir Ian
See the photo of: Prosser, Sir Ian Director;
2001Schmitz, Ronaldo
See the photo of: Schmitz, Ronaldo Director;
2001Younger, Jennie
See the photo of: Younger, Jennie Vice-president;
2001Ziegler, Jack
See the photo of: Ziegler, Jack Chairman;
2000Garnier, Jean-Pierre
See the photo of: Garnier, Jean-Pierre Chief Executive Officer;
1997Barzach, Michele
See the photo of: Barzach, Michele Director;
year
employees
<>
social impact : country
source
2009
-1341
Internal restructuring: Glaxo cuts 798 jobs in Evreux (Eure), 30 jobs in Ulis (Essonne), 13 jobs in Notre-Dame de Bondeville (Seine-Maritime), 500 medical representatives jobs and 146 at its headquarters of Marly-le-Roi, in the Yvelines.: France
Les Echos
2008
-1000
Internal restructuring: Sales jobs: United States of America
Reuters
2008
-620
Closure/Bankruptcy: GlaxoSmithKline closes its Dartford plant because ot the competition of the generic drug makers.: United Kingdom
Les Echos
2008
17000
-350
Internal restructuring: GlaxoSmithKline Plc is axing around 350 jobs in research and development as part of an ongoing restructuring program. "We continue to reshape our R&D operations to take advantage of new scientific opportunities and improve GSK's productivity. Regrettably some job reductions are necessary and we will do everything we can to support those employees who are affected," a spokesman said.:
Reuters
2007
-200
Les Echos
2006
600
Les Echos
2004
100019
-100
Internal restructuring: Cumbrian plant: United Kingdom
European Restructuring Monitor
2002
104499
-400
Internal restructuring: United Kingdom
European Restructuring Monitor
2001
100000
2001
-1800
Financial Times
1999
110000
year
employees
<>
social impact : country
source
 11 informations, access to subscribers
year
country : consequences
source
2009France : GlaxoSmithKline was judged " entirely responsible for the detrimental consequences resulting from the defect of its vaccine Engerix B" , and condemned by the court of Nanterre to give 400.000 euros to an young woman affected by multiple sclerosis after having vaccinated against hepathitis B.Les Echos
2004United States of America brand: Paxil : Glaxo avait versé 2,5 millions de dollars pour mettre fin aux poursuites de la FDA pour avoir caché les risques que présente l'anti-dépresseur Paxil administré à des enfants et adolescents.Le Revenu
year
country : consequences
source
 2 informations, access to subscribers

yearfinancial misdemeanorsalesincome buybacksource
2006   45,58,75   billion US$
2006 GlaxoSmithKline is fined 10 millions euros for "predatory pricing" by the French Commission on competition. GlaxoSmithKline sold the generic version of the Zinnat antibiotic at prices lower than its own purchase prices, in order to evict other manufacturers such as Flavelab which was selling similar generics. After Flavelab was driven out of the market, GlaxoSmithKline appreciably raised its prices over the two years which followed, recovering very largely the losses authorized for the period of predation.     Les Echos
2005   37,275,74   billion US$
2005 GSK a payé 150 millions de dollars pour solder à l'amiable un différend portant sur des accusations du gouvernement américain, selon lesquelles il aurait pratiqué des prix élevés et frauduleux sur deux de ses médicaments.     Les Echos
2005 Sued by the State of California for defrauding the state's $34 billion Medi-Cal program by inflating prices. "We're going to drag these drug companies into courts of law because they've been gouging the public," California Attorney General Bill Lockyer said at a news conference. For example, Medi-Cal paid $804.70 US for a bottle of the hypertension drug Atenolol. Providers such as doctors, clinics and pharmacists paid $33.85 US. As a result, providers reimbursed by Medi-Cal for Atenolol pocketed $770.85 US. The windfalls gave doctors, pharmacies and other providers an incentive to prescribe such drugs, which resulted in even more sales by drug makers, Lockyer said.     Bloomberg
2005 A federal judge has granted final approval to SmithKline Beecham's $65 million settlement of a class action antitrust suit brought by consumers who said they paid inflated prices for Paxil, a popular anti-depressant drug. The suit alleged that SmithKline illegally maintained a monopoly by filing a series of "sham" patent lawsuits that were designed to delay any generic version of the drug from reaching the market. Glaxo settles the suit for 14 million dollars.     Reuters
2004 Charged by the US IRS with underpaying taxes of $US 5.2 billion on US profits earned between 1989 and 1996.   39,225,26   billion US$
2004 Agreed to pay $92 million to settle antitrust cases involving the antibiotic product Augmentin.     Bizjournals.com
2004 Glaxo is facing fraud claims for suppressing at least four different studies showing that Paxil was no more effective than a placebo and at worst was harmful, while promoting heavily the drug boasting of its efficacy and safety.     The Guardian
2004 Une centaine d'employés de GSK poursuivis pour corruption et associations de malfaiteurs et soupçonnées d'être impliquées dans un système de corruption mis en place par la branche italienne du géant pharmaceutique britannique.     France 2
2003   21,444,48 0,836billion UK£
2003 Surfacturation: a changé le nom de ses médicaments pour les écouler plus cher à l'administration fédérale états-unienne: amende de 89 millions de $US.     L'Expansion
2002   21,213,92   billion Eu€
2002   2,2billion UK£The Motley Fool
2002 Evidence of a nationwide "bribery system" in which doctors allegedly prescribed 7-8% more Glaxo products each year in return for "freebies" such as Caribbean trips, stereo systems and wine.     The Guardian
2002 1600 doctors across Germany are under investigation for allegedly taking bribes such as free holidays in exchange for prescribing Glaxo drugs     Financial Times
2001   1,3billion UK£The Motley Fool
2001   29,844,5   billion US$
2000   18,080,07   billion Eu€
1999   25,8   billion Eu€
1995 Allegedly bribed Italian health ministry officials     The Guardian
yearfinancial misdemeanorsalesincomeassetsbuybacksource
 21 informations, access to subscribers
year
purpose : intermediary/lobby : institution
source
2000Limit the legal liability, no price control, no list of preferred drugs, hampers the approval and marketing of generic drugs, no drug imports, no limit to drug advertising… : Pharmaceutical Research and Manufacturers of America : : US government, congress, senate translateWashington Post
2000Lift the ban on bovine growth hormons, the moratorium on GMOs : EFPIA (European Federation of Pharmaceutical Industry Associations) : : European Commission translateEFPIA
» More influence from GlaxoSmithKline
» Influence in 2007
year
purpose : intermediary/lobby : institution
source
 2 informations, access to subscribers
» More influence from GlaxoSmithKline
» Influence in 2007
yeardonatorcountryamountsource
2006EtatFrance15 million Eu€Les Echos
yeardonatorcountryamountsource
 1 informations, access to subscribers
year
dubious practice : image
source
2007Disinformation: GlaxoSmithKline attempted to stifle and intimidate physicians who initially expressed concerns that the diabetes drug Avandia was linked to higher risk of heart attacks, the Wall Street Journal reported. As early as 2000 a Maryland doctor linked the drug to congestive heart failure. The company responded by asking the hospital's chief physician to keep that physician from talking about it with other doctors at the hospital.: Integrity in Science
2007Disinformation: In early September, "major newspapers reported the alarming news that suicides among young people were on the rise because of a precipitous drop in the use of antidepressants," writes Alison Bass. The academic study the news articles were based on concluded that new safety warnings for young people using antidepressant drugs had discouraged doctors from writing prescriptions for depressed youths. But there's a hole in that argument: "while there was indeed an upturn in suicide rates among youths ... the number of prescriptions for antidepressants in the same age group remained basically unchanged." Bass points out that the pharmaceutical companies that make antidepressants might "benefit from the latest alarm about an apparent upturn in youth suicide rates. ... These companies have an enormous stake in reversing the current FDA warnings." Pfizer, which makes the antidepressant Zoloft, did provide $30,000 for the academic study, and the study's lead authors have ties to Pfizer, GlaxoSmithKline and Wyeth Pharmaceuticals. "This isn't the first time that suicide rates have been trotted out as a public relations weapon," Bass adds. "Proponents of psychotropic drugs have long argued that suicide rates ... fell after" such drugs were introduced, though the decline began well before the drugs were widely prescribed.: Boston Globe
2005Disinformation: In Fall 2005, the company will begin "an extensive state-by-state media blitz," paralleling its "grassroots outreach." PR Week reported, "Glaxo will target local media markets in each state - outlets that do not often have the chance to communicate directly with pharmaceutical executives." GSK's Pucci said that local reporters were easier for the drug company to deal with. "These folks are hungry for news," he said. "They'll print everything we say … without the political spin." GSK hired two PR firms for the media work, but declined to name them.: Sourcewatch
2005slogan: Do more, feel better, live longer.;
2005Soutient l'exposition « Valda toujours » au musée des Arts Décoratifs - Musée de la Publicité de Paris où seront rassemblées des publicités originales sous forme d’affiches, de plaques émaillées et d’automates.: value: Culture;
2005Disinformation: Voyage gratuit pour une trentaine de journalistes français pour se familiariser avec le traitement de l'asthme au Québec: public relations: VCyberpresse
2004Disinformation: In March 2004, the Canadian Medical Association Journal published excerpts from a GSK "internal document" that advised staff "to withhold clinical trial findings in 1998 that indicated the antidepressant paroxetine (Paxil in North America and Seroxat in the UK) had no beneficial effect in treating adolescents." The GSK memo recommended, in part, that the company needed to "effectively manage the dissemination of these data in order to minimize any potential negative commercial impact" and stated that "It would be commercially unacceptable to include a statement that efficacy had not been demonstrated, as this would undermine the profile of paroxetine.": Sourcewatch
2004Disinformation: In spring 2004, GSK launched a "grassroots outreach" effort, sending "sales representatives to deliver its message in front of the religious, fraternal, and other community groups to which they belong." A year into the effort, PR Week reported that GSK's standing had improved by 13 points, according to a Harris Interactive poll. "Clearly the grassroots campaign is having an impact," said Michael Pucci, Glaxo's VP of external advocacy.: Sourcewatch
2002Disinformation: Euro RSCG Vitesse: public relations: ECB-News
2001ad budget: 1130 million US$; Advertising Age
2000ad budget: 1066 million US$; Advertising Age


Bookmark and Share    en español  en français  in italiano
translate this page in arabic chinese dutch german japanese korean russian
Legal notice © T&C 1999-2010
 CONTRIBUTIONS